Timothy P. Noyes Sells 10,000 Shares of Aerovate Therapeutics, Inc. (NASDAQ:AVTE) Stock

Aerovate Therapeutics, Inc. (NASDAQ:AVTE) CEO Timothy P. Noyes sold 10,000 shares of Aerovate Therapeutics stock in a transaction on Tuesday, April 16th. The stock was sold at an average price of $24.70, for a total transaction of $247,000.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

Timothy P. Noyes also recently made the following trade(s):

• On Monday, April 1st, Timothy P. Noyes sold 10,000 shares of Aerovate Therapeutics stock. The stock was sold at an average price of $30.00, for a total transaction of $300,000.00.

Aerovate Therapeutics Trading Up 2.1 %

AVTE stock opened at $22.05 on Friday. Aerovate Therapeutics, Inc. has a 12 month low of $9.41 and a 12 month high of $32.42. The company has a 50-day moving average price of $24.44 and a 200 day moving average price of $19.14. The stock has a market cap of $614.31 million, a PE ratio of -7.66 and a beta of 1.23.

Hedge Funds Weigh In On Aerovate Therapeutics

A number of large investors have recently made changes to their positions in the company. Rhumbline Advisers boosted its stake in shares of Aerovate Therapeutics by 4.0% during the 1st quarter. Rhumbline Advisers now owns 14,798 shares of the company’s stock worth $298,000 after purchasing an additional 566 shares during the period. Barclays PLC lifted its holdings in Aerovate Therapeutics by 22.0% during the 1st quarter. Barclays PLC now owns 4,720 shares of the company’s stock valued at $94,000 after buying an additional 850 shares in the last quarter. Charles Schwab Investment Management Inc. lifted its holdings in Aerovate Therapeutics by 3.7% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 24,641 shares of the company’s stock valued at $722,000 after buying an additional 885 shares in the last quarter. JPMorgan Chase & Co. lifted its holdings in Aerovate Therapeutics by 13.9% during the 2nd quarter. JPMorgan Chase & Co. now owns 8,070 shares of the company’s stock valued at $138,000 after buying an additional 986 shares in the last quarter. Finally, UBS Group AG lifted its holdings in Aerovate Therapeutics by 9.2% during the 4th quarter. UBS Group AG now owns 12,241 shares of the company’s stock valued at $277,000 after buying an additional 1,027 shares in the last quarter.

Wall Street Analysts Forecast Growth

A number of equities analysts have commented on the stock. Jefferies Financial Group assumed coverage on shares of Aerovate Therapeutics in a research note on Monday, March 25th. They issued a “buy” rating and a $65.00 price objective for the company. Wells Fargo & Company reissued an “overweight” rating and issued a $35.00 price objective on shares of Aerovate Therapeutics in a research note on Monday, April 1st. Finally, Wedbush reaffirmed an “outperform” rating on shares of Aerovate Therapeutics in a research note on Thursday, April 4th.

About Aerovate Therapeutics

Aerovate Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. It focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial.